Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: The significant costs of both drugs were mentioned. Nice job. Good job describing the benefits reported in the two drug studies. The two papers present a bewildering array of statistics. This story did a nice job distilling the information into a couple of very understandable sentences. Good job explaining signifcant potential harms of both drugs something competitors didn't do at all. Nice job, including linking (in the online version) to the papers in the New England Journal of Medicine. No disease-mongering of melanoma. Several independent sources cited. The story adequately explained the comparisons between both new drugs and the older dacarbazine chemo drug. Vemurafenib was described as experimental and as "expected to be approved by the FDA within a few months." Ipilimumab was explained to be approved in March and already on the market. The relative novelty of both drugs was well explained. It's clear that the story did not rely on a news release. Claim: Drugs Show Promise Slowing Advanced Melanoma

Output: The story made strong, clear attempts to report in a restrained manner, using terms/phrases such as: "notable progress" "do not cure" "might add two to several moths to expected lifespans" "To be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug." Stories about cancer perhaps especially melanoma because of its treatment challenges should balance promise with realistic context. This story did a better job of that than the competitors' efforts we reviewed.

Input: Consider Input: Paragraph: The documentary builds on Harry's work on mental health issues, which included work with brother Prince William and his wife Kate in their Heads Together campaign. Harry says the series will share "global stories of unparalleled human spirit fighting back from the darkest places" and the "opportunity for us to understand ourselves and those around us better." Earlier this year, Apple enlisted Winfrey, together with Jennifer Aniston and Steven Spielberg, to try to overcome the TV and movie streaming service business dominated by Netflix and Amazon. The service, dubbed Apple TV Plus, will feature Apple's original shows and movies. Claim: Prince Harry, Oprah work on mental health program for Apple.

Output: Kensington Palace says Britain's Prince Harry will be partnering with Oprah Winfrey to create a documentary series on mental health for Apple's new streaming service.

Input: Consider Input: Paragraph: The compound, from Danish biotech firm Santaris Pharma, works by blocking or "silencing" microRNAs tiny strands of RNA, or ribonucleic acid, that help turn genes into proteins. The ground-breaking study is the first demonstration of microRNA silencing in primates and an early endorsement of the technique. Phase I safety trials are now planned in humans. Unlike other drugs in the hotly pursued RNA interference field, the new designer molecule, known as Locked Nucleic Acid (LNA), can be given as a simple injection rather than having to be delivered direct to affected tissue. "We think LNA is a one-stop shop for silencing," Santaris Chief Executive Keith McCullagh told reporters. Scientists from Santaris and the University of Copenhagen lowered total cholesterol in African green monkeys by up to 30 percent, without ill effects, by targeting a microRNA linked to genes in the liver that are involved in cholesterol metabolism. The results were published in the journal Nature, along with other test-tube research showing that LNA effectively blocks the production of hepatitis C virus in human liver cells. Santaris intends to test its first LNA compounds in humans by the middle of this year but it will take at least five years before any medicine is ready for submission for approval. While the cholesterol effect is interesting, McCullagh said the most promising opportunity actually lay in pursuing LNA as a treatment for hepatitis C, a poorly treated viral disease that can cause serious liver damage. Further ahead, LNA could also have a role to play in other infectious diseases, as well as cancer and autoimmune disorders, since many disease-associated genes are regulated by microRNAs. "There are great prospects for future drug development both for liver diseases and other disease types, and Europe has the potential to match the USA in this area," said Mike Gait at the MRC Laboratory of Molecular Biology in Cambridge. Up until now, U.S. firms such as Alnylam Pharmaceuticals Inc and Sirna Therapeutics which was bought by Merck & Co Inc for $1.1 billion in October 2006 have led the field in RNA interference. Santaris last year signed a pact that could earn it more than $700 million with GlaxoSmithKline Plc, giving Europe's biggest drugmaker the right to develop certain products as antiviral medicines. That alliance did not include the new technology but McCullagh said Santaris could potentially extend the Glaxo deal. For a story on Santaris Pharma's possible IPO, please click on Claim: "New kind of gene ""silencing"" drug works in monkeys."
Output: A new class of drug that fine tunes the action of genes has been shown to cut cholesterol in monkeys and may fight a range of ills, including hepatitis C and perhaps cancer, scientists said on Wednesday.